The effectiveness of nab-paclitaxel plus gemcitabine and gemcitabine monotherapy in first-line metastatic pancreatic cancer treatment: A real-world evidence
Prejac, J., Tomek Hamzić, D., Librenjak, N., Goršić, I., Kekez, D. & Pleština, S. (2022). The effectiveness of nab-paclitaxel plus gemcitabine and gemcitabine monotherapy in first-line metastatic pancreatic cancer treatment: A real-world evidence. Medicine, 101. (39). doi: 10.1097/MD.0000000000030566
Prejac, Juraj, et al. "The effectiveness of nab-paclitaxel plus gemcitabine and gemcitabine monotherapy in first-line metastatic pancreatic cancer treatment: A real-world evidence." Medicine, vol. 101, no. 39, 2022. https://doi.org/10.1097/MD.0000000000030566
Prejac, Juraj, Dora Tomek Hamzić, Nikša Librenjak, Irma Goršić, Domina Kekez and Stjepko Pleština. "The effectiveness of nab-paclitaxel plus gemcitabine and gemcitabine monotherapy in first-line metastatic pancreatic cancer treatment: A real-world evidence." Medicine 101, no. 39 (2022). https://doi.org/10.1097/MD.0000000000030566
Prejac, J., et al. (2022) 'The effectiveness of nab-paclitaxel plus gemcitabine and gemcitabine monotherapy in first-line metastatic pancreatic cancer treatment: A real-world evidence', Medicine, 101(39). doi: 10.1097/MD.0000000000030566
Prejac J, Tomek Hamzić D, Librenjak N, Goršić I, Kekez D, Pleština S. The effectiveness of nab-paclitaxel plus gemcitabine and gemcitabine monotherapy in first-line metastatic pancreatic cancer treatment: A real-world evidence. Medicine [Internet]. 2022 September 30 [cited 2024 November 07];101(39). doi: 10.1097/MD.0000000000030566
J. Prejac, D. Tomek Hamzić, N. Librenjak, I. Goršić, D. Kekez and S. Pleština, "The effectiveness of nab-paclitaxel plus gemcitabine and gemcitabine monotherapy in first-line metastatic pancreatic cancer treatment: A real-world evidence", Medicine, vol. 101, no. 39, September 2022. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:002851. [Accessed: 07 November 2024]